Table 2.
Trial Features | No. of Trials | % |
---|---|---|
Phase | ||
I | 19 | 7% |
I/II | 33 | 11% |
II | 239 | 82% |
Total unique EP trials | 291* | 100% |
Sources | ||
Cooperative Groups | 141 | 48% |
Industry | 98 | 34% |
Local | 14 | 5% |
NCI-designated cancer centers | 31 | 11% |
Other | 7 | 2% |
Disease site | ||
Hematologic | 64 | 22% |
Lung | 50 | 17% |
Gastrointestinal | 43 | 15% |
Breast | 31 | 11% |
Gynecologic | 30 | 10% |
Genitourinary | 23 | 8% |
Brain | 13 | 4% |
Head and neck | 10 | 3% |
Melanoma | 8 | 3% |
Other | 19 | 7% |
Lead organization (top 10, including ties) | ||
Southwest Oncology Group | 28 | 10% |
Eastern Cooperative Oncology Group | 24 | 8% |
North Central Cancer Treatment Group | 21 | 7% |
Sarah Cannon Research Institute | 20 | 7% |
Gynecologic Oncology Group | 20 | 7% |
Radiation Therapy Oncology Group | 19 | 7% |
Cancer and Leukemia Group B | 18 | 6% |
Eli Lilly | 8 | 3% |
University of Wisconsin | 7 | 2% |
Children's Oncology Group | 6 | 2% |
Providence Health & Services | 6 | 2% |
American College of Surgeons Oncology Group | 5 | 2% |
University of Nebraska | 5 | 2% |
Abbreviations: CCOP, Community Clinical Oncology Program; EP, early-phase; NCCCP, National Cancer Institute Community Cancer Centers Program; NCI, National Cancer Institute.
Number of open EP trials at a site may also reflect EP trials open at a lead site (eg, a lead CCOP site) with which that NCCCP site is affiliated.